

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/360473539>

# Mycobacterium tuberculosis mixed infections and drug resistance in sub-Saharan Africa: a systematic review

Article in African Health Sciences · April 2022

DOI: 10.4314/ahs.v22i1.65

CITATIONS

5

READS

79

3 authors:



**Micheni Lisa Nkatha**

Kampala International University (KIU)

16 PUBLICATIONS 55 CITATIONS

[SEE PROFILE](#)



**Serawit Deyno**

Hawassa University

78 PUBLICATIONS 614 CITATIONS

[SEE PROFILE](#)



**Joel Bazira**

Mbarara University of Science & Technology (MUST)

144 PUBLICATIONS 1,467 CITATIONS

[SEE PROFILE](#)

# Mycobacterium tuberculosis mixed infections and drug resistance in sub-Saharan Africa: a systematic review

Lisa Nkatha Micheni<sup>1,2</sup>, Serawit Deyno<sup>1,3</sup>, Joel Bazira<sup>1</sup>

1. Department of Microbiology, Mbarara University of Science and Technology, Box 1410 Mbarara, Uganda.
2. Department of Microbiology and Immunology, Kampala International University Western Campus, Box 71, Bushenyi, Uganda.
3. Department of Pharmacology, Mbarara University of Science and Technology, Box 1410 Mbarara, Uganda.

## Abstract

**Background:** Sub-Saharan Africa, is a region that records high rates of TB infection. Mycobacterium tuberculosis mixed strain infection, especially when the strains involved are of different susceptibilities, is an area of great interest because it is linked with an increased risk of treatment failure and transmission of resistant strains within the population. This paper reviewed original studies that reported MTB mixed infection and heteroresistance in the region between 2010 and 2020 to understand the extent of mixed strain infection and heteroresistance in the region. This information is very critical in the control of TB and ending the TB epidemic by 2035 as per the World Health Organization's vision.

**Methods:** pubmed, Scopus, JSTOR, AJOL, and Google Scholar databases were searched through both key terms and subject headings. The literature was screened, assessed for the quality and evidence synthesized.

**Results:** Eighteen original articles were included in this review after having met the inclusion criteria. The frequency of mixed strain infection reported in these studies varied between 2.8% and 21.1% while drug resistance range between 0.06% to 19% depending on the study design and the drug susceptibility screening technique utilized. The majority of the studies (50%) utilized Spoligotyping in conjunction with MIRU-VNTR typing in the detection of mixed infections.

**Conclusion:** Despite the scarcity of data on mixed infections and heteroresistance in sub-Saharan Africa, various studies have revealed that these conditions are frequent in the region than previously thought. Given the evidence of the effect of mixed infections on drug resistance and treatment outcome, we conclude that mixed infection is an unavoidable topic for future studies.

**Keywords:** Tuberculosis; mixed infection; drug resistance.

**DOI:** <https://dx.doi.org/10.4314/ahs.v22i1.65>

**Cite as:** Micheni LN, Deyno S, Bazira J. Mycobacterium tuberculosis mixed infections and drug resistance in sub-Saharan Africa: a systematic review. *Afri Health Sci.* 2022;22(1):560-72. <https://dx.doi.org/10.4314/ahs.v22i1.65>

## Introduction

Tuberculosis (TB), was declared a global health epidemic in 1993 by the World Health Organization (WHO) and up to date it continues to be a major public health concern<sup>1</sup>. It is associated with substantial morbidity and mortality with approximately 1.45 million deaths and 10 million newly diagnosed cases annually,<sup>2,3</sup> making it the leading cause of death due to a single infectious agent worldwide<sup>3</sup>. TB infections were historically thought to be as a result of a single strain and any recurrence was as-

sumed to be due to reactivation of the same strain that caused the first episode<sup>4</sup>. Infection due to multiple strains in a patient at a single point in time was barely considered. However, in the mid-1970s it was discovered, using phage typing, that different strains of Mycobacterium tuberculosis (MTB) could infect a patient at a single point in time<sup>5</sup>.

MTB mixed strain infection is described as a disease state in which a patient harbours more than one MTB strain at the same time either as a result of a single transmission involving multiple distinct strains or as a result of multiple transmission events<sup>6</sup>. Based on the information available from strain genotype databases such as <http://www.ncbi.nlm.nih.gov/BLAST/mycobacterium.html>, there are tens of thousands of MTB strains that are in existence and capable of infecting humans<sup>7</sup>. These strains

### Corresponding author:

Lisa Nkatha Micheni,  
Department of Microbiology,  
Mbarara University of Science and Technology,  
Box 1410 Mbarara, Uganda.  
Email: [lisa.micheni@kiu.ac.ug](mailto:lisa.micheni@kiu.ac.ug)

are largely categorized into eight distinct genetic lineages (designated as L1 to L8)<sup>7,8</sup>. The different lineages are not only associated with particular geographical areas, but they also have distinct pathogenic characteristics that influence disease transmission, treatment outcomes, and antimicrobial drug resistance<sup>9-11</sup>. For instance, Lineage 1 (Indo-Oceanic) strains are known to be moderately virulent and are common in the Philippines, East Africa (also reported in Djibouti), and the Indian Ocean's rim while Lineage 2 (east Asian) is extremely virulent, more drug-resistant than other lineages and is predominant in Russia, East Asia and Central Asia<sup>12,13</sup>. Lineage 3 strains are concentrated in central Asia and East Africa while lineage 4 (Euro-American) are found in Europe, America, Africa, and the Middle East. Lineage 7 was recently discovered in Ethiopia where it is predominant<sup>14</sup> while lineages<sup>5,6</sup> are highly restricted in West Africa<sup>15</sup>. Lineage 8 (L8) consists of strains specifically adapted to infect domestic and wild animals but are capable of causing disease in humans<sup>16-18</sup>. These L8 strains include, *Mycobacterium bovis* (cattle) which currently accounts for 3 to 16% of all TB cases in sub-Saharan Africa<sup>19-21</sup> and *Mycobacterium caprae* (sheep and goats) causes approximately 2.8% of all TB cases in Africa<sup>17,22</sup>.

The advent of molecular genotyping techniques such as *Mycobacterial Interspersed Repetitive Unit-Variable Number Tandem Repeat (MIRU-VNTR)*<sup>23</sup>, *Spoligotyping*<sup>24</sup> and *Whole Genome Sequencing (WGS)*<sup>25</sup>, has enabled the differentiation of these strains and detection of mixed infection in a patient at a single point in time. Mixed strain infection is more common in patients who live in areas with high infection pressure, regardless of whether they are immunocompetent or immunosuppressed<sup>26-30</sup>. Infection pressure hereby described as the number of MTB microbes and their ability to infect people in the community, meaning that when infection pressure is high, there are many microbes and people are much more likely become infected<sup>28</sup>. Studies have shown that approximately, 10%–20% of individuals living in areas with a high TB burden are infected with more than one strain of MTB<sup>6,31</sup>. A metagenomics study conducted by Kay et al., (2015) revealed a high rate of mixed infection in Europe during the 18<sup>th</sup> century when the incidence of TB was high<sup>30</sup>. Another study conducted in South Africa, a country with a heavy TB burden, found high proportions of TB mixed infection of up to 54 %<sup>32</sup>. Despite a scarcity of data on mixed infection from countries with moderate TB bur-

den, high proportions of mixed infection have also been identified<sup>33-35</sup>. For example, a study conducted in Iran, a country with a moderate rate of TB, revealed that 27% of Iranian TB patients had mixed infection<sup>13</sup>.

Mixed strain infection has have been associated with poor treatment outcomes and treatment failure<sup>28,36-39</sup> especially if the infection is due to strains with different susceptibility patterns (sensitive and resistant strain). This condition herein referred to as heteroresistant, has been shown to play a key role in changing the drug susceptibility patterns<sup>15, 20-23</sup>. However, detection of heteroresistance can be difficult using the routine laboratory tests. For example, the GeneXpert Cepheid test, has been shown to have a low sensitivity in detecting mixed infection and a high false-negativity rate in detecting rifampin (RIF) resistance in cases of mixed infection<sup>44</sup>. This test can only reliably detect RIF resistance in clinical specimens when the MTB resistant subpopulation is > 50% of the bacilli in a sample (45–47) at a Ct value of 23.62<sup>48</sup>. Other assays such as Line probe assay and high-resolution melting analysis can detect more than 50% of heteroresistance<sup>26-28</sup>. Delayed diagnosis of mixed infection and/or heteroresistance can increase the risk of treatment failure and encourage transmission resistant strains, mainly in high-TB-burden areas<sup>52</sup> thus impeding TB control. Understanding the role of mixed infection on drug resistance and the magnitude of mixed infections in our community is essential if we are to end the TB epidemic by 2035 as envisioned by the World Health Organization's<sup>2</sup>. This review examines the available data on MTB mixed infection and heteroresistance in sub-Saharan Africa, and examines the association of mixed infection and drug resistance.

## Methods

### Search Strategy and Selection Criteria

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines<sup>52</sup> were followed. A systematic advanced search of original articles published in English focusing solely on data dating from 2010 to 2020 in various online databases such as Medline (PubMed), JSTOR, AJOL and Google Scholar (additional search) was carried out. Search key terms included 'tuberculosis' 'mixed infections' and "drug resistance" as described in Table 1. To ensure that we did not overlook any original papers that addressed the topic of mixed infection and heteroresistance, we widened our search terms to include terms such as "multiple strains," "het-

erogeneous," and "polyclonal," "multidrug-resistant" and "antimycobacterial drug resistance" which are often used as alternate terms were also used. Titles and abstracts were screened for relevance, and subsequently reviewed the full texts of potentially pertinent manuscripts. Studies were eligible for inclusion if they were carried out on humans, used original data and if they reported evidence

of mixed infection and/or drug resistance in any region within sub-Saharan Africa. Drug resistance studies that did not provide evidence of heteroresistance and information on the genotyping tool used for drug resistance analysis were excluded from the analysis. Those studies carried out in multiple countries were only included if the results were stratified by country.

**Table 1:** The database searches

Databases	Search terms	Results
PubMed	Filters: Humans; 2010-2020  #1 [MeSH Terms] tuberculosis OR "Mycobacterium tuberculosis" OR Tb #2 [All Fields] "mixed infection" OR "multiple strains" OR heterogenous OR polyclonal #3 [All Fields] "drug resistant" OR "multidrug resistant"  <b>#1 AND #2 AND #3</b>	2,561
JSTOR	Limits: Academic content: Journals; Language: English; Date range 2010 to 2020;  #1 (tuberculosis OR Tb OR "Mycobacterium tuberculosis") #2 ("mixed infection" OR "multiple strains" OR heterogenous OR polyclonal) #3 ("drug resistant" OR "multidrug resistant")  <b>#1 AND #2 AND #3.</b>	1,044
AJOL	#1 (tuberculosis OR tb OR "Mycobacterium tuberculosis") #2 ("mixed infection" OR "multiple strains" OR heterogenous OR polyclonal) #3 ("drug resistant" OR "multidrug resistant")  <b>#1 AND #2 AND #3.</b>	173
Google Scholar	Limits: Item type: Article; Articles with all words; Date range 2010 to 2020  #1 tuberculosis AND mixed infection AND drug resistance	185*

**Data extraction**

Data from selected studies were extracted using an Excel spreadsheet developed for this purpose. The extracted data include; the identity of the study (title, first author's last name and publication year), country of the study, number of samples collected and analyzed, a laboratory technique used for analysis, rate of mixed infection and TB drug-resistant cases reported. Thereafter, three categories were developed for the analysis of our findings:


mixed strain infection, TB drug resistance and an association of mixed strain infection with TB treatment/drug resistance.

**Results**

The initial search identified 3,961 articles, which were reduced to 3,395 after eliminating duplicates. After 88 reviewing titles and abstracts an extra 3,311 were excluded as irrelevant for the research topic. On full-text examina-

tions, 18 articles were selected as meeting inclusion criteria (figure 1), in which two sets of papers had similar results, were conducted in the same area, and were conducted in the same timeframe by similar researchers, and thus only one paper from each set was considered. Muwonge et al., 2013<sup>53,54</sup> conducted the first set of studies in Uganda, while the second set was conducted in Botswana<sup>29,44</sup>. Of the original eighteen articles, fourteen of the studies

reported cases of heteroresistance, four articles reported cases of mixed infection while the other six articles reported cases of polyclonal resistance or mixed infection alone. Of the four studies that showed evidence of drug resistance on different MTB genotypes, one was a multinational study<sup>55</sup>. Based on the results of the 18 articles, the rate of mixed strain infection ranged between 2.8% to 51.0% while MTB drug resistance was between 0.06% (for ethambutol resistant) and 48.9% (MDR). (Table 2).



**Fig 1:** PRISMA study selection flow diagram for screened, excluded and included studies

**Table 2:** Studies conducted within Sub-Saharan Africa on mixed tuberculosis infection and/or drug resistance; January 2010- December 2020

Sno.	Study	Country	No. of initial patients recruited/ samples	No. of samples analyzed	No. of cases with Mixed infection	%age rate of Mixed infection	No. of DR cases	% age rate of DR	Technique used
1	Mulenga et al., (2010) (60)	Zambia	361	152	5	3.2%	-	-	Spoligotyping, 15-locus MIRU-VNTR
2	Dickman et al., (2010) (61)	Uganda	113	113	11	7.1%	-	-	15-locus MIRU-VNTR
3	Mallard et al., (2010) (62)	Malawi	72 patients/ 160 sputum samples	256	2	2.8%	-	-	IS6110-RFLP, Spoligotyping
4	Hanekom et al., (2013) (63)	South Africa	535	206	31	15%	-	-	PCR methods
5*	Shin et al., (2015) (29)* <sup>1</sup>	Botswana	370	370	37	10%	55 patients	14.9% MDR	24-locus MIRU-VNTR
	Zetola et al., (2014) (44)* <sup>1</sup>	Botswana	370	370	37	10%	55 patients	14.9% MDR	Spoligotyping, 24-locus MIRU-VNTR
6*	Muwonge et al., 2013 (57)* <sup>2</sup>	Uganda	344	74	8	11.1%	(13DR; 2 MDR)	19% DR; 3% MDR	Spoligotyping, 15 loci MIRU-VNTR
	Muwonge et al., (2013) (58)* <sup>2</sup>	Uganda	344	74	12	11.1%	(13DR; 2 MDR)	19% DR; 3% MDR	Spoligotyping, 15-locus MIRU-VNTR
7	Zetola et al., (2014) (36)	Botswana	539	475	33/475	7%	483/539	88.1% MDR	DST phenotypic methods
8	Cohen et al., (2011) (64)	South Africa	240	56	5	9%	12	21% MDR	24-locus MIRU-VNTR
9	Ssegooba et al., (2015) (65)	Uganda	66	51	2	4%	3; 0	0.06% ethambutol resistant	Spoligotyping, 24-locus MIRU-VNTR
10	Guerra-Assunção et al., (2015) (66)	Malawi	1933	1471	2	0.01%	-	3.7% isoniazid resistant	IS6110-RFLP, WGS
11	Cohen et al., (2016) (67)	South Africa	500	436	92	21.1%	-	3.79% MDR	MIRU-VNTR
12	Shin et al., (2018) (68)	Botswana	299	260	25	9.6%	30	11.5% MDR	24-locus MIRU-VNTR
13	Anselmo et al., (2019) (69)	Mozambique	79	79	4 distinct spoligoty pes	-	14	17.72% MDR	Spoligotyping, Line probe assay
14	Bazira et al., (2011) (70)	Uganda	167	125	79 distinct spoligoty pes	-	8	6.4% MDR	Spoligotyping, RD analysis
15	Kidenya et al., (2019) (71)	Tanzania	78	74	6 distinct spoligoty pes	-	6DR	8.1% DR; 1.4% MDR	Spoligotyping, WGS
16	Solo et al., (2020)(72)	Zambia	274	274	Various genotypes	-	134 MDR;	48.9% MDR	Spoligotyping, LSP, WGS
17	Kigozi et al., (2018) (73)	Uganda	97	97	Various genotypes	-	38 MDR	39.2% MDR	WGS
18	Kateete et al., (2019) (59)	eSwatini, Somalia and Uganda	80	80	Various genotypes	-	40 MDR; 24 XDR	50% MDR; 30% XDR	WGS

## Discussion

### Mycobacterium tuberculosis mixed infection

Despite the scarcity of data on MTB mixed infections in Sub-Saharan Africa we identified some studies from nine countries that reported mixed infections among patients. Table 2 shows these studies and the prevalence rates of mixed strain infections reported which ranges between 2.8% (58) and 21.1%<sup>63</sup>. Detection of mixed strain infection in TB patients is greatly influenced by the molecular technique utilised to differentiate between the strains. Different molecular techniques ranging from IS6110 restriction fragment length polymorphism (RFLP) typing to Whole Genome Sequencing (WGS), are in use for the detection of mixed strain infection. In the last two decades, the IS6110 RFLP typing technique, which is based on analysis of the variation in the copy number of IS6110 unique insertion sequence of MTB<sup>70</sup>, has significantly been applied in the detection of mixed strain infections and is considered the gold standard<sup>71,72</sup>. This technique is highly discriminatory and produces consistent and repeatable results. However, it is time-consuming since it requires large amounts of DNA that can only be obtained through extensive cultures and suffers from problems of interpretability and portability of the complex banding patterns<sup>73</sup>. Furthermore, it does not provide adequate discrimination among isolates with low ( $\leq$

5) IS6110 copy numbers, a problem that is only partially addressed by using Spoligotyping as a secondary method<sup>74,75</sup>. Spoligotyping is a cheap and robust method<sup>76</sup>, but it has a low discriminatory power hence generally not recommended for use on its own in the study of mixed infections<sup>77</sup>. Analysis of the Mycobacterial Interspersed Repetitive Units (MIRUs) that are located mainly in intergenic regions spread throughout the MTB genome is another technique that is in use. This technique has been shown to have high discriminatory power, quick turnaround time and reliable identification of mixed infections<sup>54,71,78,79</sup>. The use of this technique as a first-line tool in combination with Spoligotyping has been shown to provide sufficient discrimination for large-scale prospective MTB genotyping in the majority of cases<sup>73</sup>. The original MIRU-VNTR typing systems made use of limited sets of loci<sup>4, 6-9</sup> hence low discriminatory power<sup>80</sup>. However, with time there was a development of more reliable systems that analyses extensive sets of 11 to 24 VNTR loci<sup>23,75,81-83</sup>. A system based on analysis of the 12 MIRU-VNTR loci is currently the most commonly epidemiological tool in use technique<sup>78,81,84</sup>, however, alternative sets of MIRU-VNTR loci such as 15 and 24 loci that enhance the discrimination of unrelated isolates are also in use<sup>23,72,85,86</sup>. Whole Genome Sequencing (WGS) analysis, is another molecular technique that was invented

two decades ago. This technique provides high-resolution data on mixed infection as it gives a detailed overview of the different strains of mixed infection that cannot be evaluated using other methods<sup>25,87</sup>. Its major drawbacks that can restrict its use especially in many developing nations is its high operational cost and difficulties in interpreting the generated data<sup>88,89</sup>. Studies presented in this review utilized more than one technique to identify mixed infection whereby half of them (10/20;50%) utilized Spoligotyping as one of the typing methods. Five of these studies utilized Spoligo typing in conjunction with MIRU-VNTR and a rate of 4% (61) to 11.1%<sup>53</sup> of mixed infection was identified. One study that utilized IS6110-RFLP in conjunction with WGS detected a 0.01% rate of mixed infection<sup>62</sup> while a study that utilized MIRU-VNTR alone identified a 21.1% rate of mixed infection<sup>63</sup>.

Detection of mixed strain infection is also influenced by the sampling approach. Prior studies have shown that detection of mixed infections vary depending on whether one is either using direct sputum samples or cultures<sup>90</sup>. According to Farman farmaei and his colleagues, genotyping done on cultures could result in bias since the use of several culture collections or culture on numerous media can reduce the likelihood of identifying mixed infections. It has also been shown that the type of culture media used has a significant impact on the detection of mixed infections, whereby, LJ media was more sensitive than other media such as MGIT media<sup>59,90</sup> and that the clonal composition changes significantly after culture<sup>91</sup>. Furthermore, evidence of different strains in a clinical specimen is highly dependent on the collection and handling/processing of the sample. For instance, collecting a single, low-volume sputum sample containing a large amount of upper airway secretions may substantially reduce the chance of detecting a mixed infection<sup>33</sup>. Shamputa et al., showed that increasing the number of sputum samples collected increases the likelihood of detecting mixed infections and that analyzing several sputum samples from various cavities within the lung could profoundly increase the likelihood of detecting a mixed infection. Studies reviewed here, relied on the collection of sputum samples from multiple pre-treatment specimens<sup>61</sup> and typing of cultures from smear-positive individuals, collected serially over time<sup>33,44,63,64</sup> and thus increased the sensitivity of their assay.

## **Mycobacterium tuberculosis drug Resistance**

Drug resistance is a situation that is of great concern since it poses a big challenge in the control of TB and ending of the TB epidemic by 2035 as envisioned by the WHO (2). This review identified fourteen studies that showed the presence of either one or more types of drug resistance. These include monoresistance, multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB). Monoresistance is defined as the resistance of MTB to one antimycobacterial drug such as rifampin (RIF) or isoniazid (INH) for example RIF-resistant TB (RR-TB) -describes MTB that is susceptible to INH but resistant to RIF. MDR-TB is defined as concurrent resistance of MTB to first-line drugs rifampicin (RIF) and isoniazid (INH). XDR-TB is defined as MDR-TB strains with additional resistance to a fluoroquinolone and at least one of the injectable aminoglycosides<sup>92,93</sup> and was first identified in 2006<sup>94</sup>. Table 2 shows the studies that reported drug resistance/heteroresistance and the prevalence rate. From these studies the reported rate of monoresistance ranged from 0.06% for ethambutol<sup>61</sup> to 3.7% for isoniazid<sup>62</sup> while the MDR cases ranged between 1.4% (67) to 48.9%<sup>68</sup>. It is worth noting that the study by Kateete et al., (2019) that reported a 50% and 30% rate of MDR and XDR respectively, analyzed only samples that had been deemed as drug resistance<sup>55</sup> hence may not necessarily reflect the actual prevalence at the community level. While much progress has been made in the recent past to understand the drug resistance situation in sub-Saharan Africa<sup>47,95-98</sup>, adequate data is still lacking due to weak surveillance and diagnostic capabilities<sup>40</sup>. For instance, rifampicin and isoniazid resistance is well monitored and described in most countries, either through continuous surveillance or periodic surveys unlike resistance to ethambutol and Pyrazinamide (PZA), the other two first-line drugs, which are not routinely monitored and thus poorly described<sup>99</sup>.

## **Association of mixed infection with TB treatment/ drug resistance**

Despite the limited data on the effect of mixed infections (particularly when strains with distinct drug susceptibility patterns are involved) and limited sensitivity of current methods for detecting mixed infections, researchers have been able to identify deleterious effects of mixed infections for individuals who are affected and potential consequences for disease control. Using strain-specific PCR

to detect mixed infections and detailed treatment data, Van Rie and his colleagues demonstrated that in patients harbouring both MDR and susceptible strains, the MDR strain population was able to survive and grow during a treatment with first-line antibiotics and upon a switch to second-line regimens, the susceptible strains were able to reemerge<sup>100</sup>. Apart from demonstrating MDR strains' relative fitness deficits in these patients, the findings revealed that mixed infections with strains of different resistance phenotypes could compromise treatment outcomes when using standard treatment regimens. Other studies have also shown that drug susceptibility patterns change through the presence or absence of antibiotic pressure, which determines the dominant growth of the coinfecting strain<sup>6,36,101</sup>. This implies that mixed infections with resistant strains could have poor clinical outcomes because the existence of any underlying drug resistance greatly decreases the efficacy of standardized antibiotic regimens and increases the risk of acquired resistance. Furthermore, there is a possibility of a reemergence of the drug-resistant strains when another regimen is introduced as a result antibiotic pressure<sup>6,28</sup> or increase the risk of the drug-resistant strain acquiring additional drug resistance mutations<sup>28</sup>. In addition to the ability of multiple-strain infections to impair treatment efficacy, it has been hypothesised that superinfection can occur some time after the primary infection, resulting in disease progression and endogenous reactivation of the primary infection. This means that the primary infection cannot provide immunity against a secondary infection<sup>38</sup>.

Mixed infections not only have an impact on the patient, but also on the community by negatively impacting on antituberculosis interventions and promoting transmission of resistant strains. Colijn et al.<sup>102</sup>, for instance, used a simple mathematical model to demonstrate how TB mixed infections promote the spread of resistant strains when interventions which affects drug-resistant and drug-sensitive strains differently such as isoniazid preventive therapy (IPT), are used, result in an increased ability of the resistant strain to take over. Another model study by Cohen and his colleagues<sup>103</sup> on the possible effects of new tuberculosis vaccines, they discovered that in mixed infections, by allowing multiple strain types to coexist, there was possibility of eroding the expected benefits of the new vaccine that does not sufficiently cover all circulating strain types, since the vaccine would be more likely lead to strain replacement. Therefore, despite the much

difficulty in detecting MTB strains with different susceptibility profiles especially using the routine culture-based drug-susceptibility techniques<sup>28</sup> it is very crucial to determine MTB mixed infection in patients and detect heteroresistance to ensure an appropriate antibiotic therapy regimen is chosen and eventually improving the treatment outcome and reduce the opportunity community transmission of drug resistant strains.

## Conclusion

Despite the scarcity of data on mixed infections and heteroresistance in Sub-Saharan Africa, studies have revealed that these conditions are more frequent in the region than previously thought. Given the evidence of the effect of mixed infections on drug resistance and treatment outcome, we conclude that mixed infection is an unavoidable topic for future studies.

## Limitations

Our findings are limited by the relatively few number of studies conducted in sub-Saharan Africa and due to the large heterogeneity amongst the included studies, this prohibited us from conducting a meta-analysis.

## Abbreviations

DNA = Deoxyribonucleic acid  
DR-TB = Drug resistant - tuberculosis  
DST = Drug susceptibility tests  
INH = Isoniazid  
IS6110-RFLP = Insertion sequence 6110- restriction fragment length polymorphism  
MDR-TB = Multidrug resistant - tuberculosis  
MIRU- VNTR = Mycobacterial Interspersed Repetitive Unit - Variable Number Tandem Repeat  
MTB = Mycobacterium tuberculosis  
MTBC = Mycobacterium tuberculosis complex  
PCR= Polymerase chain reaction  
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
PZA = Pyrazinamide  
RIF = Rifampicin  
RR-TB = Rifampicin resistant tuberculosis  
TB = Tuberculosis  
WHO = World health organization  
WGS = Whole-genome sequencing  
XDR-TB = Extensively drug-resistant – tuberculosis  
XXDR-TB = Totally drug-resistant – tuberculosis



## Authors' contributions

MLN Conceived and designed the study; searched, extracted, analyzed data, drafted the manuscript and approved the final version; JB Conceived and designed the study; Revised the manuscript and approved the final version; SD Searched, extracted analyzed data, drafted the manuscript and approved the final version.

## Ethical approval

Not required.

## Conflict of interests

The authors declare that no conflicts of interest exist.

## References

1. Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. 2017;(February):354–73.
2. WHO. Global Tuberculosis Report 2016. Global Tuberculosis Report 2016. 2016.
3. WHO. Global Tuberculosis Report 2019. 2019.
4. Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Vol. 95, *American Review of Respiratory Disease*. 1967. p. 729–45.
5. Bates JH, Stead WW, Rado TA. Phage type of tubercle bacilli isolated from patients with two or more sites of organ involvement. Vol. 114, *American Review of Respiratory Disease*. 1976. p. 353–8.
6. Tarashi S, Fateh A, Mirsaedi M, Siadat SD, Vaziri F. Mixed infections in tuberculosis: The missing part in a puzzle. *Tuberculosis* [Internet]. 2017;107:168–74. Available from: <http://dx.doi.org/10.1016/j.tube.2017.09.004>
7. Bouakaze C, Keyser C, De Martino SJ, Sougakoff W, Veziris N, Dabernat H, et al. Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot minisequencing-based assay. *J Clin Microbiol*. 2010;48(5):1758–66.
8. Stucki D, Malla B, Hostettler S, Huna T, Feldmann J, Yeboah-Manu D, et al. Two new rapid SNP-typing methods for classifying mycobacterium tuberculosis complex into the main phylogenetic lineages. *PLoS One*. 2012;7(7).
9. Wirth T, Hildebrand F, Allix-Beguec C, Wlbeling F, Kubica T, Kremer K, et al. Origin, Spread and Demography of the Mycobacterium tuberculosis Complex. *PLoS Pathog*. 2008;4(9):1–10.
10. Gehre F, Antonio M, Faïhun F, Odoun M, Uwiz-eye C, de Rijk P, et al. The First Phylogeographic Population Structure and Analysis of Transmission Dynamics of *M. africanum* West African 1- Combining Molecular Data from Benin, Nigeria and Sierra Leone. *PLoS One*. 2013;8(10):8–13.
11. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, Gey Van Pittius NC, et al. Patients with Active Tuberculosis often Have Different Strains in the Same Sputum Specimen. *Am J Respir Crit Care Med*. 2004;169(5):610–4.
12. Rahim Z, Zaman K, Van Der Zanden AGM, Möllers MJ, Van Soolingen D, Raqib R, et al. Assessment of population structure and major circulating phylogeographical clades of Mycobacterium tuberculosis complex in Bangladesh suggests a high prevalence of a specific subclone of ancient *M. tuberculosis* genotypes. *J Clin Microbiol*. 2007;45(11):3791–4.
13. Zamani S, Nasiri MJ, Haeili M, Kazemian H, Darban-Sarokhalil D, Fooladi AA, et al. Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among TB patients in Iran, using 15 loci MIRU-VNTR. *Int J Mycobacteriology*. 2015;4:119.
14. Nebenzahl-guimaraes H, Yimer SA, Holm-hansen C, Beer J De, Brosch R, Soolingen D Van. Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name : ‘ Aethiops vetus . ’ 2016;(April):1–8.
15. Gagneux S. Ecology and evolution of Mycobacterium tuberculosis. *Nat Rev Microbiol* [Internet]. 2018;16(4):202–13. Available from: <http://dx.doi.org/10.1038/nrmicro.2018.8>
16. Alexander KA, Laver PN, Michel AL, Williams M, Helden PD Van, Warren RM. Mycobacterium tuberculosis Complex Pathogen , *M. mungi*. *Emerg Infect Dis*. 2010;16(8):1296–9.
17. Prodinger WM, Indra A, Koksalan OK, Kilicaslan Z, Richter E. Mycobacterium caprae infection in humans. *Expert Rev Anti Infect Ther*. 2014;12(12):1501–13.
18. Pullen MF, Boulware DR, Sreevatsan S, Bazira J. Tuberculosis at the animal-human interface in the Ugandan cattle corridor using a third-generation sequencing platform: A cross-sectional analysis study. *BMJ Open*. 2019;9(4):1–7.
19. El-Sayed A, El-Shannat S, Kamel M, Castañeda-Vazquez MA, Castañeda-Vazquez H. Molecular Epidemiology of Mycobacterium bovis in Humans and Cattle. *Zoonoses Public Health*. 2016;63(4):251–64.
20. Ayele WY, Neill SD, Zinsstag J, Weiss MG, Pavlik I.

- Bovine tuberculosis: An old disease but a new threat to Africa. *Int J Tuberc Lung Dis.* 2004;8(8):924–37.
21. Cadmus S, Oluwatoyin Akinseye V, van Soolingen D. Mycobacterium bovis in humans and M. Tuberculosis in animals in Nigeria: An overview from 1975–2014. *Int J Tuberc Lung Dis.* 2019;23(11):1162–70.
  22. Muller B, Durr S, Hattendorf J, Laise CJM, Parsons SDC, van Helden PD, et al. Zoonotic Mycobacterium bovis-induced tuberculosis in humans. *Emerg Infect Dis.* 2013;19(6):899–908.
  23. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. *J Clin Microbiol.* 2006;44(12):4498–510.
  24. Huard RC, Lazzarini LC de O, Butler WR, van Soolingen D, Ho JL. PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions Huard, R. C., Lazzarini, L. C. de O., Butler, W. R., van Soolingen, D., & Ho, J. L. (2003). *PCR-based method to differentiate the s.* *J Clin Microbiol.* 2003;41(4):1637–50.
  25. Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J, et al. Whole Genome Sequencing versus Traditional Genotyping for Investigation of a Mycobacterium tuberculosis Outbreak: A Longitudinal Molecular Epidemiological Study. *PLoS Med.* 2013;10(2).
  26. Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, et al. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. *J Clin Microbiol.* 2012;50(3):995–1002.
  27. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. *PLoS One.* 2009;4(5).
  28. Van Rie A, Victor TC, Richardson M, Johnson R, Van Der Spuy GD, Murray EJ, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. *Am J Respir Crit Care Med.* 2005;172(5):636–42.
  29. Shin SS, Modongo C, Ncube R, Sepako E, Klausner JD, Zetola NM. Advanced immune suppression is associated with increased prevalence of mixed-strain mycobacterium tuberculosis infections among persons at high risk for drug-resistant tuberculosis in Botswana. *J Infect Dis.* 2015;211(3):347–51.
  30. Kay GL, Sergeant MJ, Zhou Z, Chan JZ, Millard A, Spigelman M, et al. Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe. *Nat Commun.* 2015;(6):6717.
  31. McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. *Pathog Dis.* 2017;75(3):1–16.
  32. Stavrum R, Mphahlele M, Øvreås K, Muthivhi T, Fourie PB, Weyer K, et al. High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. *J Clin Microbiol.* 2009;47(6):1848–56.
  33. Shamputa IC, Jugheli L, Sadradze N, Willery E, Portals F, Supply P, et al. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. *Respir Res.* 2006;7:1–10. PubMed
  34. Tazi L, Reintjes R, Bañuls AL. Tuberculosis transmission in a high incidence area: A retrospective molecular epidemiological study of Mycobacterium tuberculosis in Casablanca, Morocco. *Infect Genet Evol.* 2007;7(5):636–44. PubMed
  35. Berh MA. Tuberculosis due to multiple strains. Vol. 169, *American Journal of Respiratory and Critical Care Medicine.* 2004.
  36. Zetola NM, Modongo C, Moonan PK, Ncube R, Matlhagela K, Sepako E, et al. Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests. *J Infect Dis.* 2014;209(11):1754–63. PubMed
  37. Sivanand. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet.* 2018;392(10150):821–34. PubMed
  38. Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. *Clin Microbiol Rev.* 2012;25(4):708–19. PubMed
  39. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM. Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. *Emerg Infect Dis.* 2015;21(6):992–1001. PubMed
  40. Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario AR, et al. Multidrug-resistant tuber-

- culosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013-2017. *BMC Infect Dis.* 2019;19(1):1–10. PubMed
41. Varghese B, Supply P, Allix-Béguet C, Shoukri M, Al-Omari R, Herbawi M, et al. Admixed Phylogenetic Distribution of Drug Resistant Mycobacterium tuberculosis in Saudi Arabia. *PLoS One.* 2013;8(2):1–8.
  42. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: A systematic review. *Thorax.* 2006;61(2):158–63.
  43. Yang XY, Li YP, Mei YW, Yu Y, Xiao J, Luo J, et al. Time and spatial distribution of multidrug-resistant tuberculosis among Chinese people, 1981-2006: A systematic review. *Int J Infect Dis.* 2010;14(10):828–37.
  44. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by genexpert MTB/RIF are associated with poor clinical outcomes. *J Clin Microbiol.* 2014;52(7):2422–9.
  45. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, et al. Evaluation of the cepheid xpert MTB/RIF assay for direct detection of mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol.* 2011;49(4):1621–3.
  46. Pandey P, Pant ND, Rijal KR, Shrestha B, Kattel S, Banjara MR, et al. Diagnostic Accuracy of GeneXpert MTB/RIF assay in comparison to conventional drug susceptibility testing method for the diagnosis of multidrug-resistant tuberculosis. *PLoS One.* 2017;12(1):8–13.
  47. Jahan H, Jhora ST, Habib ZH, Yusuf MA, Ahmed I, Farzana A, et al. Diagnostic Evaluation of GeneXpert MTB/RIF Assay for the Detection of Rifampicin Resistant <i>Mycobacterium tuberculosis</i> among Pulmonary Tuberculosis Patients in Bangladesh. *J Tuberc Res.* 2016;04(01):55–60.
  48. Najjingo I, Muttamba W, Kirenga BJ, Nalunjogi J, Bakesiima R, Olweny F, et al. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. *PLoS One.* 2019;14(5):1–11.
  49. Galarza M, Fasabi M, Levano KS, Castillo E, Barreda N, Rodriguez M, et al. High-resolution melting analysis for molecular detection of multidrug resistance tuberculosis in Peruvian isolates. *BMC Infect Dis* [Internet]. 2016;16(1):1–6. Available from: <http://dx.doi.org/10.1186/s12879-016-1615-y>
  50. Arefzadeh S, Azimi T, Nasiri MJ, Nikpor Z, Dabiri H, Doustdar F, et al. High-resolution melt curve analysis for rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a single-centre study in Iran. *New Microbes New Infect* [Internet]. 2020;35:100665. Available from: <https://doi.org/10.1016/j.nmni.2020.100665>
  51. Nagai Y, Iwade Y, Hayakawa E, Nakano M. High resolution melting curve assay for rapid detection of drug-resistant Mycobacterium tuberculosis. 2013;
  52. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg.* 2010;8(5):336–41.
  53. Muwonge A, Kankya C, Olea-popelka F, Biffa D, Ssengooba W, Berit D, et al. Molecular investigation of multiple strain infections in patients with tuberculosis in Mubende district, Uganda. *Infect Genet Evol* [Internet]. 2013;17:16–22. Available from: <http://dx.doi.org/10.1016/j.meegid.2013.03.039>
  54. Muwonge A, Malama S, Johansen TB, Kankya C, Biffa D, Ssengooba W, et al. Molecular Epidemiology, Drug Susceptibility and Economic Aspects of Tuberculosis in Mubende District, Uganda. *PLoS One.* 2013;8(5):1–10.
  55. Kateete DP, Kamulegeya R, Kigozi E, Katabazi FA, Lukoye D, Sebit SI, et al. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016). *BMC Pulm Med.* 2019;19(1):1–9.
  56. Mulenga C, Shamputa IC, Mwakazanga D, Kapata N, Portaels F, Rigouts L. Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, Zambia. *BMC Infect Dis.* 2010;10.
  57. Dickman KR, Nabyonga L, Kateete DP, Katabazi FA, Asiimwe BB, Mayanja HK, et al. Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in. *BMC Infect Dis.* 2010;10(349):1–8.
  58. Mallard K, McNERNEY R, Crampin AC, Houben R, Ndlovu R, Munthali L, et al. Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. *J Clin Microbiol.* 2010;48(12):4512–8.
  59. Hanekom M, Streicher EM, Van de Berg D, Cox H, McDermid C, Bosman M, et al. Population Structure of Mixed Mycobacterium tuberculosis Infection Is Strain Genotype and Culture Medium Dependent. *PLoS One.* 2013;8(7):5–10.

60. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixed-strain Mycobacterium tuberculosis infections among patients dying in a Hospital in KwaZulu-Natal, South Africa. *J Clin Microbiol*. 2011;49(1):385–8.
61. Ssengooba W, Cobelens FG, Nakiyingi L, Mboowa G, Armstrong DT, Manabe YC, et al. High genotypic discordance of concurrent mycobacterium tuberculosis isolates from sputum and blood of HIV-infected individuals. *PLoS One*. 2015;10(7):1–14.
62. Guerra-Assunção JA, Houben RMGJ, Crampin AC, Mzembe T, Mallard K, Coll F, et al. Recurrence due to relapse or reinfection with mycobacterium tuberculosis: A whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. *J Infect Dis*. 2015; 211(7):1154–63.
63. Cohen T, Chindelevitch L, Misra R, Kempner ME, Galea J, Moodley P, et al. Within-host heterogeneity of mycobacterium tuberculosis infection is associated with poor early treatment response: A prospective cohort study. *J Infect Dis*. 2016;213(11):1796–9.
64. Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. *J Infect Dis*. 2018;218(12):1974–82.
65. Anselmo LMP, Conceição EC, Namburete E, Feliciano C, Spindola S, Sola C, et al. Mycobacterium tuberculosis spoligotypes and drug-resistant characterization from beira compared to genotypes circulating in Mozambique. *Rev Soc Bras Med Trop*. 2019;52:10–3 PubMed .
66. Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda. *BMC Infect Dis*. 2011;11.
67. Kidenya BR, Mshana SE, Fitzgerald DW, Ocheretina O. Genotypic Drug Resistance using Whole-genome Sequencing of Mycobacterium tuberculosis Clinical Isolates from North-western Tanzania. *Tuberc*. 2019;109(March):97–101.
68. Solo ES, Suzuki Y, Kaile T, Bwalya P, Lungu P, Chizimu JY, et al. Characterization of Mycobacterium tuberculosis genotypes and their correlation to multidrug resistance in Lusaka, Zambia. *Int J Infect Dis* [Internet]. 2020;102:489–96. Available from: <https://doi.org/10.1016/j.ijid.2020.10.014>
69. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. *PLoS One*. 2018;13(5):1–17.
70. Van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology. *J Clin Microbiol*. 1993;31(2):406–9.
71. Gopaul KK, Brown TJ, Gibson AL, Yates MD, Drobniewski FA. Progression toward an improved DNA amplification-based typing technique in the study of Mycobacterium tuberculosis epidemiology. *J Clin Microbiol*. 2006;44(7):2492–8.
72. Christianson S, Wolfe J, Orr P, Karlowsky J, Levett PN, Horsman GB, et al. Evaluation of 24 locus MIRU-VNTR genotyping of Mycobacterium tuberculosis isolates in Canada. *Tuberculosis* [Internet]. 2010;90(1):31–8. Available from: <http://dx.doi.org/10.1016/j.tube.2009.12.003>
73. Kremer K, Van Soolingen D, Frothingham R, Haas WH, Hermans PWM, Martín C, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: Interlaboratory study of discriminatory power and reproducibility. *J Clin Microbiol*. 1999;37(8):2607–18.
74. Gori A, Esposti AD, Bandera A, Mezzetti M, Sola C, Marchetti G, et al. Comparison between spoligotyping and IS6110 restriction fragment length polymorphisms in molecular genotyping analysis of Mycobacterium tuberculosis strains. *Mol Cell Probes*. 2005;19(4):236–44.
75. Faksri K, Drobniewski F, Nikolayevskyy V, Brown T, Prammananan T, Palittapongarnpim P, et al. Genetic diversity of the Mycobacterium tuberculosis Beijing family based on IS6110, SNP, LSP and VNTR profiles from Thailand. *Infect Genet Evol* [Internet]. 2011;11(5):1142–9. Available from: <http://dx.doi.org/10.1016/j.meegid.2011.04.007>
76. Tanaka MM, Francis AR. Detecting emerging strains of tuberculosis by using spoligotypes. *Proc Natl Acad Sci U S A*. 2006;103(41):15266–71.
77. Abadia E, Zhang J, Ritacco V, Kremer K, Ruimy R, Rigouts L, et al. The use of microbead-based spoligotyping for Mycobacterium tuberculosis complex to evaluate the quality of the conventional method: Providing guidelines for Quality Assurance when working on membranes. *BMC Infect Dis*. 2011;11:1–8 PubMed .
78. Supply P. Multilocus Variable Number Tandem Repeat Genotyping of Mycobacterium tuberculosis. Inst

- Pasteur Lille [Internet]. 2005;(May):73. Available from: <http://www.miru-vntrplus.org/MIRU/miruinfor.faces>
79. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human minisatellite-like regions in the *Mycobacterium tuberculosis* genome. *Mol Microbiol*. 2000;36(3):762–71. PubMed
80. Kremer K, Arnold C, Cataldi A, Gutiérrez MC, Haas WH, Panaiotov S, et al. Discriminatory power and reproducibility of novel DNA typing methods for *Mycobacterium tuberculosis* complex strains. *J Clin Microbiol*. 2005;43(11):5628–38. PubMed
81. Allix-Béguec C, Harmsen D, Weniger T, Supply P, Niemann S. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of *Mycobacterium tuberculosis* complex isolates. *J Clin Microbiol*. 2008;46(8):2692–9. PubMed
82. Chen YY, Chang JR, Huang WF, Kuo SC, Su IJ, Sun JR, et al. Genetic diversity of the *mycobacterium tuberculosis* beijing family based on snp and VNTR typing profiles in asian countries. *PLoS One*. 2012;7(7):1–7. PubMed
83. Dickman KR, Nabyonga L, Kateete DP, Katabazi FA, Asimwe BB, Mayanja HK, et al. Detection of multiple strains of *Mycobacterium tuberculosis* using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. *BMC Infect Dis*. 2010;10(December).
84. Kato-Maeda M, Metcalfe JZ, Flores L. Genotyping of *Mycobacterium tuberculosis*: applications in epidemiologic studies. *Futur Microbiol* [Internet]. 2011;6(2):203–16. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22712667>
85. Yasmin M, Le Moullec S, Siddiqui RT, De Beer J, Sola C, Refrégier G. Quick and cheap MIRU-VNTR typing of *Mycobacterium tuberculosis* species complex using duplex PCR. *Tuberculosis* [Internet]. 2016;101:160–3. Available from: <http://dx.doi.org/10.1016/j.tube.2016.10.003>
86. Nabyonga L, Kateete DP, Katabazi FA, Odong PR, Whalen CC, Dickman KR, et al. Determination of circulating *Mycobacterium tuberculosis* strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTR. *BMC Res Notes*. 2011;4:4–9 PubMed
87. Nikolayevskyy V, Kranzer K, Niemann S, Drobniowski F. Whole genome sequencing of *Mycobacterium tuberculosis* for detection of recent transmission and tracing outbreaks: A systematic review. *Tuberculosis* [Internet]. 2016;98:77–85. Available from: <http://dx.doi.org/10.1016/j.tube.2016.02.009>
88. Lu H, Giordano F, Ning Z. Oxford Nanopore MinION Sequencing and Genome Assembly. *Genomics, Proteomics Bioinforma* [Internet]. 2016;14(5):265–79. Available from: <http://dx.doi.org/10.1016/j.gpb.2016.05.004>
89. Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor Countries: Challenges and opportunities. *Clin Microbiol Rev*. 2011;24(2):314–50. PubMed
90. Farmanfarmaei G, Kargarpour Kamakoli M, Sadegh HR, Masoumi M, Abdollahimi F, Fateh A, et al. Bias in detection of *Mycobacterium tuberculosis* polyclonal infection: Use clinical samples or cultures? *Mol Cell Probes* [Internet]. 2017;33:1–3. Available from: <http://dx.doi.org/10.1016/j.mcp.2017.01.002>
91. Martín A, Herranz M, Jesús M, Serrano R, Bouza E, García D, et al. The clonal composition of *Mycobacterium tuberculosis* in clinical specimens could be modified by culture. 2010;90:201–7.
92. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, et al. Predicting extensively drug-resistant *Mycobacterium tuberculosis* phenotypes with genetic mutations. *J Clin Microbiol*. 2014;52(3):781–9. PubMed
93. Wollenberg KR, Desjardins CA, Zalutskaya A, Slodovnikova V, Oler AJ, Quiñones M, et al. Whole-genome sequencing of *mycobacterium tuberculosis* provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. *J Clin Microbiol*. 2017;55(2):457–60. PubMed
94. Aminu AI, Tukur AD. Second line drug sensitivity test of multidrug resistant tuberculosis (MDR-TB) isolates using proportional method. *Bayero J Pure Appl Sci*. 2019;11(1):64.
95. Kidenya BR, Webster LE, Behan S, Kabangila R, Peck RN, Mshana SE, et al. Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa. *Tuberculosis* [Internet]. 2014;94(1):1–7. Available from: <http://dx.doi.org/10.1016/j.tube.2013.08.009>
96. Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. *Infect Genet Evol* [Internet]. 2012;12(4):686–94. Available from: <http://dx.doi.org/10.1016/j.meegid.2011.07.019>
97. Vorkas C, Kayira D, van der Horst C, Hoffman I, Hosseinipour M, Kanyemba C, et al. Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, Malawi. *Malawi Med J*. 2012;24(2):21–4.

98. Sharma M, Kumar D, Bohra GK, Meena DS, Bhambu SK. Study of the prevalence of Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB) in Western Rajasthan using line probe assay. *Journal of Family Medicine and Primary Care*. 2020. p. 1093–7.
99. Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, et al. A global perspective on pyrazinamide resistance: Systematic review and meta-analysis. *PLoS One*. 2015;10(7):1–16.
100. Van Rie N, Warren R, Madelene R, Victor TC, Gie RP, Enarson DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. *N Engl J Med*. 1999;341(16):1174–9.
101. Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed infections are associated with poor treatment outcomes among newly diagnosed tuberculosis patients independent of pre-treatment heteroresistance. Oxford University Press for the Infectious Diseases Society of America. 2018.
102. Colijn C, Cohen T, Murray M. Latent coinfection and the maintenance of strain diversity. *Bull Math Biol*. 2009;71(1):247–63.
103. Cohen T, Colijn C, Murray M. Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. *Proc Natl Acad Sci U S A*. 2008;105 (42):16302–7.